

PRESS RELEASE

Lund 26 February 2019

Spago Nanomedical to present preclinical data for SpagoPix at ECR

Spago Nanomedical AB (publ) will present preclinical data for SpagoPix at the conference European Congress of Radiology (ECR) this week.

The presentation, in the form of a poster with the title "Efficacy and safety profile of SN132D, a novel nanoparticle MRI contrast agent", includes preclinical data that collectively show that the product candidate SN132D is safe and efficient at dose levels corresponding to clinically relevant doses. The poster can be viewed here https://postereng.netkey.at/esr/viewing/index.php?module=viewing_poster&task=&pi=146808&searchkey=9d11a6231519212ecd4097e24f03a33c

ECR is the largest radiology conference in Europe which last year gathered over 28,000 participants from 130 countries. This year's conference takes place in Vienna on February 27 to March 3 and puts women in focus.

A study was recently published in European Journal of Inorganic Chemistry showing that the signal strength (relaxivity) of SN132D is among the highest reported for manganese-containing contrast agents and far higher than those of the clinically used gadolinium-based agents.

On February 19, initiation of the first clinical trial with SN132D was approved by the Swedish Medical and Pharmaceutical Agency. The trial will be conducted at the Uppsala University Hospital in Sweden and will include up to 20 patients with breast cancer.

For further information, please contact Mats Hansen CEO Spago Nanomedical AB, +46 46 81188, mats.hansen@spagonanomedical.se.

Spago Nanomedical (Spotlight Stock Market, Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company's development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects

to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.

SpagoPix is a nanoparticle-based contrast agent with manganese with potential to improve cancer diagnosis using magnetic resonance tomography (MRI). By offering high precision and superior enhancement of tumors and metastases in MRI-images, the chances of correct diagnosis increase. Improved MRI diagnostics increase the chances of effective treatment for the patient. SpagoPix is also free from gadolinium, an element that may cause unwanted side effects and has caused regulatory agencies to issue warnings or withdraw products from the market.

For further information, see www.spagonanomedical.se.